查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466528

自行注射药物市场：按类型、应用、通路、治疗领域应用分类 - 全球预测 2024-2030

Self-injections Market by Type (Auto-Injectors, Needle-free Injectors, Pen Injectors), Usage (Disposable, Reusable), Distribution Channel, Therapeutic Areas Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年自行注射药物市场规模为540亿美元，预计2024年将达606.4亿美元，2030年将达1,248.7亿美元，复合年增长率为12.72%。

自行注射药物是指在没有医疗专业人员帮助的情况下，自行透过肌肉注射、皮下注射或静脉注射给药的产品。自行注射药物用于需要定期、长期照护的治疗，例如用于治疗糖尿病的胰岛素、用于荷尔蒙补充疗法和不孕症治疗的荷尔蒙以及用于慢性疾病的生物製药。自註射器被广泛用于增强自主性，并且可以透过消除医疗保健提供者的管理来提高治疗依从性。近年来，由于慢性病的增加、家庭保健的需求、药物输送技术的进步以及越来越多的患者喜欢自行注射，自行注射毒品的使用率有所增加。然而，研发所需的高额投资、对病人安全和舒适的担忧以及生技药品低温运输储存和物流的需求限制了自行注射药物的产品渗透。数位化和对以患者为中心的认识创造了将智慧技术整合到自行注射设备中的机会。专注于连接的创新可以提供资料收集、病患监测和依从性跟踪，从而实现自行注射药物的个人化治疗方法。此外，政府对自行注射药物的支持性核准进一步扩大了市场范围。

主要市场统计
基准年[2023] 540亿美元
预测年份 [2024] 606.4亿美元
预测年份 [2030] 1248.7亿美元
复合年增长率（%） 12.72%

类型 慢性病管理越来越偏好笔型注射器

自动注射器的设计易于使用，让您只需最少的训练即可注射精确剂量的药物。自动注射器用于在紧急情况下输送救生药物。需要即时可靠的药物管理（通常无需医疗保健专业人员的帮助）的患者对自动注射器的需求量很大。无针注射器是传统注射器注射的替代方案，不需要针头。无针注射器透过薄薄的高压注射液穿透皮肤来输送药物。有针头恐惧症的人主要喜欢无针注射器，而需要频繁注射的人，例如糖尿病患者，可能会经历针头疲劳。注射笔广泛用于慢性疾病的治疗，并允许自行注射胰岛素和生长激素。笔式註射器可携带、隐藏且相对易于使用，这对需要定期给药同时保持积极生活方式的患者很有吸引力。穿戴式註射器，也称为贴片帮浦，是一种紧密贴合患者身体的装置，可在较长时间内提供连续或受控的药物输送。穿戴式註射器主要用于需要长期治疗的患者。自动注射器和笔式註射器因其易用性和可靠性而通常受到青睐。另一方面，无针和可穿戴注射器适合寻求侵入性较小或更灵活的药物输送方法的患者。

用途：越来越多使用一次性自行注射，以避免交叉污染的风险。

抛弃式自动注射器是一次性注射器，因其方便、安全和降低交叉污染的风险而受到青睐。需要短期药物治疗或优先考虑低注射器维护的患者通常选择一次性自动注射器。对于感染疾病风险高的疾病，首选一次性注射器。可重复使用的自动注射器是多用途系统，是需要长期用药的慢性病患者的首选。可重复使用的自动注射器具有成本效益，需要定期维护，并且经久耐用。可重复使用的注射器是长期给药方案的首选。一次性注射器方便又安全，特别是对于不需要长期用药的患者。

分销管道：自行注射药品新渗透线上平台

医院药房主要为与医疗机构直接相连的住院患者和门诊病人提供服务。在住院期间接受自行注射治疗的患者通常会直接从医院药房获得最初的自行注射设备。需要自行注射设备使用专门指导的患者以及寻求额外支持和指导的患者更喜欢医院药房。电子商务的兴起延伸到了製药业，网路药局提供便利、谨慎和低廉的价格。网路药局特别适合已经习惯自行注射方案、喜欢宅配的患者。优先考虑便利性、行动不便或行动不便且有稳定的自行注射方案的患者更有可能选择网路药局。私人诊所提供个人化护理，并为希望与值得信赖的医疗保健提供者保持连续性的患者提供服务。私人诊所有利于接受自行注射治疗，这需要医疗保健专业人员的持续监测和追踪。医院药房因其方便的访问和患者教育资源而受到青睐，在线药房因其便利和潜在的成本节省而受到青睐，而私人诊所则因其个性化的持续护理而受到青睐。

治疗应用：扩大自行注射药物在荷尔蒙问题治疗的使用

自行注射疗法对于治疗自体免疫疾病（包括类风湿性关节炎和红斑性狼疮）至关重要。生物製药，包括Adalimumab和Etanercept，透过自行注射来管理发炎和改变疾病进展。在爱滋病的治疗中，自行注射抗逆转录病毒药物製剂有可能透过提供较低频率的给药选择来提高依从性。自行注射肾上腺素自动注射器是严重过敏患者的救命设备。自行注射药物可以在发生过敏反应时立即进行治疗，以防止潜在的致命性过敏反应。对于肿瘤患者来说，自行注射药物如颗粒细胞增生因子（G-CSF）可以帮助控制化疗引起的嗜中性白血球低下症。自行注射减少了频繁就诊的需要，并支持癌症治疗的连续性。自行注射疗法治疗包括克隆氏症在内的肠躁症，使用发炎和免疫抑制药物，对于控制症状和诱导长期缓解至关重要。含有β干扰素的自行注射药物是多发性硬化症患者治疗方法的主要支柱，有助于控制症状并减缓疾病进展。

在干癣中，自行注射生物製药针对免疫系统内的特定途径来抑制过度的发炎反应。自行注射紧急药物旨在发生危机时快速给药，例如肾上腺素、升糖素和纳洛酮自动注射器，用于治疗急性过敏反应、严重低血糖和药物过量摄取。肾上腺素注射器是过敏性休克（严重且可能危及生命的过敏反应）期间的第一道防线。自行注射偏头痛治疗可快速缓解偏头痛症状。自行注射药物比内服药物更快地阻止偏头痛发作，这对症状严重或出现噁心和呕吐的患者有益。荷尔蒙补充疗法中使用的自行注射药物可以提供稳定剂量的睪固酮、雌激素和黄体酮等激素，这对荷尔蒙缺乏症患者和跨性别患者有益。 β干扰素自行注射主要用于治疗多发性硬化症、减少发炎并降低復发频率。促红血球生成素（EPO）自行注射对于治疗慢性肾臟病病患者的贫血至关重要。促红血球生成素 (EPO)自行注射可刺激红血球生成，有助于减少输血需求。滤泡刺激素（FSH）自行注射在不孕症治疗中发挥重要作用。它刺激女性卵巢的生长和男性精子发生。低分子肝素自行注射为长期门诊抗凝血提供了一个易于使用的选择，通常用于血栓症形成风险的患者的抗凝血。自行注射胰岛素是糖尿病管理的基本治疗方法，由于可以根据血糖值和饮食摄取量来注射胰岛素，因此具有弹性并能提供良好的血糖控制。对于骨质疏鬆症患者，自行注射副甲状腺素可以透过刺激新骨生长来帮助提高骨骼密度，这对于治疗严重骨质疏鬆症至关重要。帕金森氏症患者可以从自行注射药物中受益，这些药物可以缓解症状并减缓疾病的进展。

区域洞察

美洲的自行注射药物市场受到以患者为中心的护理、先进的医疗基础设施以及需要患者友好型管理的生物製药的日益核准的推动。消费者越来越意识到自我护理的选择，包括方便的自我注射器。政府为缩短住院时间和促进自我注射药物所做的努力也促进了美洲自行注射药物的普及。在欧盟（EU），人口老化、慢性病盛行率上升以及对自我管理的日益偏好正在支持自动注射器市场的成长。欧盟严格的法律规范确保了自行注射装置的高安全标准。此外，一些欧盟国家正在积极实施病患教育计划，以促进自行注射的采用。在中东和非洲，医疗基础设施的大规模投资以及与文明病的增加表明自动注射器市场的成长前景良好。在亚太地区，快速的经济成长和不断增长的医疗保健支出是自行注射药品市场的主要驱动因素。政府对药物创新的重视和慢性病的激增正在推动需求。此外，技术先进的医疗保健系统和人口老化正在支持亚太地区的自动注射器市场。

FPNV定位矩阵

FPNV定位矩阵对于评估自行注射药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对自行注射药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.自行注射药品市场规模及预测如何？

2.自行注射药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.自行注射药品市场的技术趋势和法规结构是什么？

4.自行注射药品市场主要厂商的市场占有率是多少？

5. 进入自行注射药品市场的适当型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性疾病和类风湿性关节炎的快速传播
      • 用于不孕症治疗的自行注射药物的广泛使用
    • 抑制因素
      • 产品召回的潜在风险
    • 机会
      • 世界各地政府正在核准自行注射
      • 自动注射器的技术进步
    • 任务
      • 与自行注射药物相关的认识有限和管理挑战
  • 市场区隔分析
    • 类型：在慢性病管理中越来越偏好笔式註射器
    • 用途：一次性自行注射的使用越来越多，以避免交叉污染的风险
    • 通路：自行注射毒品在网路平台的普及
    • 治疗领域的应用：自行注射药物治疗荷尔蒙问题的应用正在扩大
  • 市场趋势分析
    • 糖尿病和慢性病的增加正在增加美洲对自行注射药物的需求
    • 增加对亚太地区医疗保健基础设施和自行注射药物器材创新的投资
    • 欧洲、中东和非洲地区政府支持核准自行注射药物
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章自行注射药品市场：依类型

  • 自动注射器
  • 无针注射器
  • 笔式註射器
  • 穿戴式註射器

第七章自行注射药品市场应用

  • 一次性的
  • 可重复使用的

第八章自行注射药品市场：依通路

  • 医院药房
  • 网路药房
  • 私人诊所

第九章依治疗领域自行注射药品市场应用

  • 自体免疫疾病
  • 急救药品
  • 荷尔蒙补充疗法

第十章 美洲自行注射药品市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太自行注射药品市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲/中东/非洲自行注射药品市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • 美光生物医学公司获得资金生产无针疫苗
    • Enable Injections 首次获得美国食品药物管理局(FDA)核准
    • Altaviz 推出新型药物输送自动注射器平台
    • FDA核准用于 PNH 治疗的自用内置注射器 pegcetacoplan
    • Civica 与 Ipsomed 合作开发胰岛素注射笔
    • Eitan Medical完成穿戴式註射器业务转型
    • Coherus 宣布在美国推出 UDENYCA 自动注射器
    • Ypsomed 透过综合人因服务增强自行注射设备平台
    • Viridian Therapeutics 宣布与药物传输创新者 Enable Injections 合作
    • 美国FDA核准Tezspire 使用预填充笔进行自我给药
    • Philips Medisize 推出笔式註射器平台，扩大产品系列，旨在降低药品成本、风险和市场壁垒

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-03050D1B2DB4

[195 Pages Report] The Self-injections Market size was estimated at USD 54.00 billion in 2023 and expected to reach USD 60.64 billion in 2024, at a CAGR 12.72% to reach USD 124.87 billion by 2030.

Self-injections refer to the products used to administer medication to themselves intramuscularly, subcutaneously, or intravenously without the immediate assistance of healthcare professionals. Self-injections are used for treatments that require regular and long-term care, such as insulin for diabetes, hormones for hormone replacement therapy and fertility treatments, and biologics for chronic conditions. Self-injection devices are widely used to increase autonomy and can improve treatment adherence by eliminating the need for healthcare provider administration. An elevating prevalence of chronic diseases, the need for home-based healthcare, advancements in drug delivery technology, and a growing patient preference for self-administration have improved the usage of self-injections in recent years. However, the requirement for significant investment in research and development, patient safety and comfort concerns, and the need for cold chain storage and logistics for biologics limit the product penetration of self-injections. Recognition of digitization and patient-centricity leads to opportunities for integrating smart technology into self-injection devices. Innovations focusing on connectivity can provide data collection, patient monitoring, and adherence tracking, guiding personalized treatment modalities for self-injections. Moreover, the supportive government approvals for self-injections are further expanding the scope of the market.

KEY MARKET STATISTICS
Base Year [2023] USD 54.00 billion
Estimated Year [2024] USD 60.64 billion
Forecast Year [2030] USD 124.87 billion
CAGR (%) 12.72%

Type: Rising preference for pen injectors to manage chronic diseases

Auto-injectors are designed for convenient use and can administer a precise dose of medication with minimal training. Auto-injectors are used for the delivery of life-saving drugs in emergencies. The need-based preference for auto-injectors is high among patients who require immediate and reliable administration of drugs, often without the assistance of healthcare professionals. Needle-free injectors offer an alternative to traditional syringe injections, removing the need for needles. Needle-free injectors use a high-pressure, narrow jet of the injection liquid to penetrate the skin to deliver the medication. Individuals with needle phobia mainly prefer needle-free injectors or those who require frequent injections, such as diabetic patients who may otherwise experience needle fatigue. Pen injectors are widely used to manage chronic diseases, allowing insulin or growth hormone self-administration. Pen injectors are portable, discreet, and relatively easy to use, appealing to patients who need to administer medication regularly while maintaining an active lifestyle. Wearable injectors, also known as patch pumps, are devices that adhere to the patient's body and provide continuous or controlled delivery of drugs over an extended period. Wearable injectors are primarily used by patients who require long-term therapies. Auto-injectors and pen injectors are generally favored for their ease of use and reliability. In contrast, needle-free and wearable injectors cater to patients seeking a less invasive or more flexible approach to medication delivery.

Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination

Disposable self-injection devices are single-use injectors preferred for their convenience, safety, and the reduced risk of cross-contamination. Disposable self-injection devices are often chosen by patients requiring short-term medication regimens or those prioritizing the ease of not having to manage the maintenance of the device. Disposable injectors are preferred for diseases with a high risk of infection transmission. Reusable self-injection devices are multi-use systems that offer cost benefits over time and are favored by patients with chronic conditions requiring long-term medication delivery. Reusable self-injection devices are cost-effective, necessitate regular maintenance and are designed for durable use. Reusable injectors are preferred for long-term medication regimens. Disposable injectors offer convenience and safety, especially for patients not requiring long-term medication.

Distribution Channel: Emerging penetration of self-injections on online platforms

Hospital pharmacies primarily serve inpatients and outpatients directly connected to medical facilities. Patients who have been prescribed self-injection therapies during a hospital stay often receive their initial supply of self-injection equipment directly from the hospital pharmacy. Patients requiring specialized instruction on the use of self-injection devices or seeking high-touch support and guidance prefer hospital pharmacies. The rise of eCommerce has extended to the pharmaceutical field, with online pharmacies offering convenience, discretion, and lower prices. Online pharmacies are particularly well-suited for those who are already familiar with their self-injection regimen and prefer home delivery. Patients who prioritize convenience, have mobility and transportation challenges or have a stable self-injection regime choose online pharmacies highly. Private clinics offer personalized care and cater to patients looking for a certain continuity of care with a healthcare provider they trust. Private clinics can be beneficial for receiving self-injection therapies that require consistent monitoring and follow-up with the healthcare practitioner. Hospital pharmacies are preferred for their immediate accessibility and patient education resources, online pharmacies for convenience and potential cost savings, and private clinics for personalized, ongoing care.

Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues

Self-injection therapies are pivotal for the treatment of autoimmune diseases, including rheumatoid arthritis and lupus. Biological agents, including adalimumab and etanercept, are administered via self-injection to manage inflammation and modify disease progression. In the management of AIDS, self-injectable formulations of antiretroviral drugs may enhance adherence by providing less frequent dosing options. Self-injectable epinephrine auto-injectors are life-saving devices for individuals with severe allergies. Self-injections allow for immediate treatment in the case of an allergic reaction, preventing potentially fatal anaphylaxis. For oncology patients, self-injectables such as granulocyte colony-stimulating factors (G-CSF) help manage chemotherapy-induced neutropenia. Self-administration can mitigate the need for frequent healthcare visits and support the continuity of cancer treatment. Self-injectable therapies in the treatment of irritable bowel disorders, including Crohn's disease, involve anti-inflammatory and immunosuppressive drugs, which are vital in controlling symptoms and inducing long-term remission. Self-administered injectable medications, including beta-interferon, are a mainstay in the treatment regimen for multiple sclerosis patients to assist in managing symptoms and slow the progression of the disorder.

In psoriasis, self-injectable biologics target specific pathways within the immune system to reduce the overactive inflammatory response. Self-injectable emergency drugs, designed for rapid administration in crises, include treatments for acute allergic reactions, severe hypoglycemia, and narcotic overdoses, exemplified by epinephrine, glucagon, and naloxone auto-injectors, respectively. Epinephrine auto-injectors are the first line of defense during anaphylactic shocks, a severe, potentially life-threatening allergic reaction. Self-injectable treatments for migraines offer rapid relief of migraine symptoms. Self-injections can abort migraine attacks more quickly than oral medications, which is beneficial for patients with severe symptoms or those experiencing nausea and vomiting. Self-injectables used in hormone replacement therapies provide a consistent delivery method for hormones, including testosterone, estrogen, or progesterone, benefiting patients with hormonal deficiencies or in transgender care. Beta-interferon self-injections are used primarily to treat multiple sclerosis, reduce inflammation, and decrease the frequency of relapse episodes. Erythropoietin (EPO) self-injectables are essential for patients with chronic kidney disease to combat anemia. Erythropoietin (EPO) self-injectables stimulate red blood cell production and help to reduce the need for blood transfusions. Self-injectable follicle-stimulating hormone (FSH) plays a crucial role in fertility treatments. It stimulates ovary follicle growth in women and spermatogenesis in men. Low molecular weight heparin self-injections are commonly used for anticoagulation in patients at risk for thrombosis to provide an easy-to-use option for long-term outpatient anticoagulation therapy. Self-injected insulin is a cornerstone treatment for diabetes management that allows individuals to dose insulin according to their blood glucose levels and dietary intake, providing flexibility and better glycemic control. For osteoporosis patients, self-injected parathyroid hormone can help improve bone density by stimulating new bone growth, an essential aspect of managing severe osteoporosis. Parkinson's disease patients may benefit from self-injectable medications that can provide symptomatic relief or slow disease progression.

Regional Insights

The self-injections market in the Americas is driven by a strong emphasis on patient-centric care, advanced healthcare infrastructure, and an increase in biologic drug approvals that require patient-friendly administration. Consumers are becoming increasingly aware of self-care options, including self-injection devices, which align with convenience. Government initiatives to reduce hospital stays and promote self-administration of medication also contribute to the penetration of self-injections in the Americas. In the European Union, market growth for self-injection devices is supported by an aging population, the prevalence of chronic diseases, and a strong inclination toward self-management of these conditions. The EU's rigorous regulatory framework ensures high safety standards for self-injection devices. Furthermore, several EU countries have been active in running patient education programs to encourage the adoption of self-injection practices. In the Middle East and Africa, substantial investments in healthcare infrastructure and an increasing incidence of lifestyle-related diseases show promising growth for the self-injections market. In the Asia-Pacific region, rapid economic growth and increased healthcare expenditure are major drivers for the self-injections market. The government's emphasis on pharmaceutical innovation and the surging prevalence of chronic diseases are boosting demand. Furthermore, a technologically advanced healthcare system and an aging population enable the market for self-injection devices in the Asia Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Self-injections Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Self-injections Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Self-injections Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Antares Pharma, Inc. by Halozyme, Inc., AstraZeneca plc, Baxter International, Inc., Becton, Dickinson and Company, Credence MedSystems, Inc., DALI Medical Devices Ltd., Eli Lilly and Company, Enable Injections, Inc., Gerresheimer AG, GlaxoSmithKline plc, Insulet Corporation, Johnson & Johnson Services, Inc., Medmix AG by Sulzer Ltd., Merck KGaA, Molex LLC by Koch Industries, Inc., Mylan N.V. by Viatris Inc., Novo Nordisk A/S, Owen Mumford Limited, PenJet Corporation, Pfizer Inc., PharmaJet, Inc., Recipharm AB, Sanofi S.A., SCHOTT AG, SHL Medical AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services, Inc., and Ypsomed Group.

Market Segmentation & Coverage

This research report categorizes the Self-injections Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Auto-Injectors
    • Needle-free Injectors
    • Pen Injectors
    • Wearable Injectors
  • Usage
    • Disposable
    • Reusable
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Private Clinics
  • Therapeutic Areas Application
    • Autoimmune Diseases
      • AIDS
      • Allergies
      • Cancer
      • Irritable Bowel Disorders
      • Multiple Sclerosis
      • Psoriasis
    • Emergency Drugs
      • Anaphylactic Socks
      • Migraine
    • Hormone Replacement Therapies
      • Beta-Interferon
      • Erythropoietin
      • Follicle Stimulating Hormone
      • Heparin
      • Insulin
      • Parathyroid Hormone
      • Parkinson's
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Self-injections Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Self-injections Market?

3. What are the technology trends and regulatory frameworks in the Self-injections Market?

4. What is the market share of the leading vendors in the Self-injections Market?

5. Which modes and strategic moves are suitable for entering the Self-injections Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid prevalence of chronic diseases and rheumatoid arthritis
      • 5.1.1.2. Wide availability of self-injections for fertility treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing government approvals for self-injections worldwide
      • 5.1.3.2. Technological advancements in self-injection devices
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and administration challenges associated with self-injections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising preference for pen injectors to manage chronic diseases
    • 5.2.2. Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination
    • 5.2.3. Distribution Channel: Emerging penetration of self-injections on online platforms
    • 5.2.4. Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues
  • 5.3. Market Trend Analysis
    • 5.3.1. Rising incidents of diabetes and chronic diseases creating need for self-injections in the Americas
    • 5.3.2. Growing investment in healthcare infrastructure and innovation in self-injections devices in APAC region
    • 5.3.3. Supportive government approvals for self-injections in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Self-injections Market, by Type

  • 6.1. Introduction
  • 6.2. Auto-Injectors
  • 6.3. Needle-free Injectors
  • 6.4. Pen Injectors
  • 6.5. Wearable Injectors

7. Self-injections Market, by Usage

  • 7.1. Introduction
  • 7.2. Disposable
  • 7.3. Reusable

8. Self-injections Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Private Clinics

9. Self-injections Market, by Therapeutic Areas Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Emergency Drugs
  • 9.4. Hormone Replacement Therapies

10. Americas Self-injections Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Self-injections Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Self-injections Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Micron Biomedical Receives Funds To Produce Needle-Free Vaccines
    • 13.3.2. Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
    • 13.3.3. Altaviz introduces New Auto-Injector Platform For Drug Delivery
    • 13.3.4. FDA Approves On-Body Injector for Self Administration of Pegcetacoplan for PNH
    • 13.3.5. Civica Partners With Ypsomed For Insulin Injection Pen
    • 13.3.6. Eitan Medical Completes Transition of Wearable Injectors Business
    • 13.3.7. Coherus Announces U.S. Launch of UDENYCA Autoinjector
    • 13.3.8. Ypsomed Enhances Self-Injection Device Platforms With Integrated Human Factors Services
    • 13.3.9. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
    • 13.3.10. US FDA Approves Tezspire For Self-Administration Using Pre-Filled Pen
    • 13.3.11. Phillips-Medisize Expands Product Portfolio with Launch of a Pen Injector Platform Designed to Lower Pharma Costs, Risks and Market Barriers

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. SELF-INJECTIONS MARKET RESEARCH PROCESS
  • FIGURE 2. SELF-INJECTIONS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SELF-INJECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SELF-INJECTIONS MARKET DYNAMICS
  • FIGURE 7. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. SELF-INJECTIONS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. SELF-INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SELF-INJECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SELF-INJECTIONS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL SELF-INJECTIONS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL SELF-INJECTIONS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL SELF-INJECTIONS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PEN INJECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL SELF-INJECTIONS MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL SELF-INJECTIONS MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISPOSABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REUSABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ALLERGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ALLERGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL SELF-INJECTIONS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL SELF-INJECTIONS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL SELF-INJECTIONS MARKET SIZE, BY IRRITABLE BOWEL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL SELF-INJECTIONS MARKET SIZE, BY IRRITABLE BOWEL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PSORIASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ANAPHYLACTIC SOCKS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ANAPHYLACTIC SOCKS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MIGRAINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL SELF-INJECTIONS MARKET SIZE, BY BETA-INTERFERON, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL SELF-INJECTIONS MARKET SIZE, BY BETA-INTERFERON, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL SELF-INJECTIONS MARKET SIZE, BY FOLLICLE STIMULATING HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL SELF-INJECTIONS MARKET SIZE, BY FOLLICLE STIMULATING HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HEPARIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL SELF-INJECTIONS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL SELF-INJECTIONS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARATHYROID HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARATHYROID HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARKINSON'S, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARKINSON'S, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 85. AMERICAS SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 86. AMERICAS SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 100. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 101. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 102. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 105. BRAZIL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. BRAZIL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 109. BRAZIL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. BRAZIL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. BRAZIL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. BRAZIL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. BRAZIL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 114. BRAZIL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 115. BRAZIL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 116. BRAZIL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 119. CANADA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. CANADA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. CANADA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 122. CANADA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 123. CANADA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 124. CANADA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 125. CANADA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. CANADA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. CANADA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 128. CANADA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 129. CANADA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 130. CANADA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 133. MEXICO SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. MEXICO SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. MEXICO SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 136. MEXICO SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 137. MEXICO SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. MEXICO SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. MEXICO SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. MEXICO SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. MEXICO SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 142. MEXICO SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 143. MEXICO SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 144. MEXICO SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 147. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 150. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 151. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 156. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 157. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 158. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 159. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 160. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 161. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 162. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 182. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 188. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 190. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 192. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 193. CHINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. CHINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. CHINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 196. CHINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 197. CHINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. CHINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. CHINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. CHINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. CHINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 202. CHINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 203. CHINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 204. CHINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 205. CHINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 206. CHINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 207. INDIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. INDIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. INDIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 210. INDIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 211. INDIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. INDIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. INDIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. INDIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. INDIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 216. INDIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 217. INDIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 218. INDIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 219. INDIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 220. INDIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 221. INDONESIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. INDONESIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. INDONESIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 224. INDONESIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 225. INDONESIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. INDONESIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. INDONESIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. INDONESIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. INDONESIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 230. INDONESIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 231. INDONESIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 232. INDONESIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 233. INDONESIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 234. INDONESIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 235. JAPAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. JAPAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. JAPAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 238. JAPAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 239. JAPAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. JAPAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. JAPAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. JAPAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. JAPAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 244. JAPAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 245. JAPAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 246. JAPAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 247. JAPAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 248. JAPAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 249. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 252. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 253. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 258. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 259. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 260. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 261. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 262. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 266. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 267. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 272. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 273. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 274. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 276. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 277. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 280. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 281. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 282. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 283. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 286. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 287. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 288. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 289. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 290. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 294. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 295. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 300. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 301. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 302. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 303. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 304. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 305. TAIWAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. TAIWAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. TAIWAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 308. TAIWAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 309. TAIWAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 310. TAIWAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 311. TAIWAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. TAIWAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. TAIWAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 314. TAIWAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 315. TAIWAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 316. TAIWAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 317. TAIWAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 318. TAIWAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 319. THAILAND SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. THAILAND SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. THAILAND SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 322. THAILAND SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 323. THAILAND SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 324. THAILAND SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 325. THAILAND SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. THAILAND SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. THAILAND SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 328. THAILAND SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 329. THAILAND SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 330. THAILAND SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 331. THAILAND SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 332. THAILAND SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 333. VIETNAM SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. VIETNAM SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. VIETNAM SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 336. VIETNAM SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 337. VIETNAM SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 338. VIETNAM SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 339. VIETNAM SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 340. VIETNAM SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 341. VIETNAM SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 342. VIETNAM SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 343. VIETNAM SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 344. VIETNAM SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-203